🟢 Quantum BioPharma is trading 10.62% up today after renewed attention to FDA clearance for its Phase 2 Lucid-MS trial

Quantum BioPharma is trading 10.62% up at $3.54 after renewed attention to FDA clearance for its Phase 2 Lucid-MS trial in multiple sclerosis.

• A September 14 press-release promotion highlighted the investigational therapy’s potential myelin-protecting and repair mechanism.
• The company emphasized it can proceed directly to a randomized, placebo-controlled study.
• The broader market is modestly lower, making the company-specific catalyst the primary explanation.